NOVALGINA ® Metamizole

NOVALGINA ® is a drug based on sodium noramidopirina methanesulfonate (metamizole)

THERAPEUTIC GROUP: Non-steroidal analgesics, pyrazolones

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions NOVALGINA ® Metamizole

NOVALGINA ® is indicated in the short-term symptomatic treatment of acute painful states on a low and modest inflammatory basis.

Action mechanism NOVALGINA ® Metamizole

Metamizole, also commonly known as dipyrone, is an active ingredient whose therapeutic classification has been at the center of many debates for many years, given the difficulty of combining it with anti-inflammatory drugs or non-steroidal analgesics.

In any case, once taken orally, it is rapidly absorbed at the intestinal level in about 90 minutes, and distributed evenly between the various tissues, where it performs an action:

Anti-inflammatory, thanks to its ability to inhibit cyclooxygenases and thus reduce the concentrations of chemical mediators endowed with vasopermeabilization, vasodilator and chemotactic activity;
Analgesic, reducing the production of molecules such as bradykinin capable of activating the peripheral receptor endings of nociceptors and desensitizing even at the central level the pain threshold;
Antipyretic, lowering the concentrations of cytokines such as IL1 and molecules such as PGE2, responsible for the hyperthermia associated with modulation of the hypothalamic thermoregulatory center;
Spasmolytic, as demonstrated by myorelaxing activity on intestinal and respiratory smooth muscles from recent experimental evidence.

After completing its biological and therapeutic actions, metamizole is appropriately remodeled to the liver level and excreted mainly via the kidneys.

Studies carried out and clinical efficacy

1. THE DIPIRONE IN THE TREATMENT OF EMICRANIA

Expert Rev Neurother. 2012 Feb; 12 (2): 159-67.

Work that shows how the simultaneous administration of caffeine and dipyrone can be effective and well tolerated in the treatment of severe and moderate migraine.

2. THE MODERATE ANTI-PYRETIC ACTIVITY OF DIPIRONE

J Pediatr (Rio J). 2011 Jan-Feb; 87 (1): 36-42. Epub 2011 Jan 11.

Clinical trial that demonstrates how the dipirone, despite having no side effects and therefore particularly indicated in pediatric patients, presents a very modest antipyretic activity, especially when compared to other active ingredients such as ibuprofen

3. THE DIPIRONE IN THE POST-OPERATIVE PAIN

Cochrane Database Syst Rev. 2010 Sep 8; (9): CD003227.

Work that demonstrates how the intake of a single 500 mg dipyrone dose can guarantee a reduction in post-operative pain in over 70% of treated patients, thus being both effective and safe.

Method of use and dosage

NOVALGINA ®

Oral drops of 500 mg of metamizole per ml of solution;

Metamizole 500 mg tablets;

Suppositories 1 g of metamizole;

Suppositories from 300 mg of metamizole.

The dosage schemes to be used vary according to the patient's physiopathological conditions and the severity of the clinical picture.

As for NOVALGINA ® in drops we recommend taking 20-40 drops in adults for 3-4 times a day, for tablets 1-2 tablets up to 4 times a day for suppositories instead 1 suppository up to 3 times per day.

In children and infants the dosage should be defined by your doctor on a case-by-case basis.

Warnings NOVALGINA ® Metamizole

The treatment based on NOVALGINA ® should be understood as a symptomatic therapy of short duration, useful for overcoming acute painful episodes, sustained by inflammatory processes.

The use of the drug prolonged over time, or at particularly high doses, could expose the patient to the risk of serious side effects, seriously complicating the clinical picture that may already be present.

Consequently, in order to reduce the incidence and severity of the various adverse reactions associated with metamizole therapy, it is advisable to take NOVALGINA ® on a full stomach if possible and for periods of time not exceeding a few days.

Particular caution should be recommended in all those patients suffering from cardiovascular, coagulative, renal, hepatic, allergic and gastrointestinal diseases, in which NOVALGINA ® therapy could be associated with a higher incidence of complications.

If unwanted adverse reactions occur, the patient should immediately contact their doctor, with whom they can evaluate the possibility of suspending the drug therapy in progress.

PREGNANCY AND BREASTFEEDING

In light of the numerous experimental and clinical studies that demonstrate the potential side effects of therapy with non-steroidal anti-inflammatory drugs on fetal health, we do not recommend the use of NOVALGINA ® during pregnancy, and in particular in the third trimester, and in the subsequent period of breastfeeding at otherwise.

Interactions

Patients taking NOVALGINA ® should pay particular attention to the possible co-administration of ciclosporin, given the possible drug interactions responsible for the decrease in plasma concentrations and the therapeutic efficacy of cyclosporins, and of alcohol due to possible interactions.

Contraindications NOVALGINA ® Metamizole

Taking NOVALGINA ® is contraindicated in case of hypersensitivity to the active substance or to one of its excipients, angioedema, peptic ulcer, history of intestinal bleeding, ulcerative colitis, Crohn's disease or previous history for the same diseases, cerebrovascular bleeding, hemorrhagic diathesis or concomitant anticoagulant therapy, renal insufficiency, liver failure, glucose deficiency 6 phosphate dehydrogenase, asthma, hypophosphataemia and viral infections.

Undesirable effects - Side effects

Despite the common clinical practice does not show particularly significant adverse reactions after taking, according to the appropriate indications, NOVALGINA ®, it is necessary to remember how the therapy with non-steroidal anti-inflammatory drugs can determine the appearance of side effects, sometimes even serious, to load of:

Gastrointestinal system with gastric pyrosis, gastralgia, nausea and vomiting, constipation and in more severe cases ulcers and hemorrhages;
Hematopoietic apparatus with increased bleeding time accompanied in severe cases by pan cytopenia;
Sensory system with loss of hearing and sight, headache, insomnia, drowsiness, confusion and tremors;
Integumentary system with erythema, rash, urticaria and in severe cases bullous reactions;
Cardiovascular system subjected to an increased risk of cerebro and cardiovascular events.